Only PVS1, PM4, and BP3 were adjudicated. No applicable MSH3 VCEP or gene-specific framework was available; the generic ClinGen SVI PVS1 framework was used for the consequence assessment. No applicable MSH3-specific VCEP or gene-specific functional-evidence specification was identified, so generic ACMG/AMP principles were used. No validated variant-specific functional assay with interpretable abnormal or normal results was found; computational SpliceAI output does not satisfy PS3 or BS3. No applicable MSH3-specific VCEP or gene-specific computational-evidence specification was identified, so the supplied generic ACMG/ClinGen-SVI calibration thresholds were used. The intronic consequence selects SpliceAI as the sole PP3/BP4 path; the SpliceAI maximum delta of 0.163 falls between the supplied PP3 supporting and BP4 supporting cutoffs. BP7 is upstream not_applicable because the variant is not synonymous. No applicable MSH3-specific VCEP or gene framework was available, so the supplied generic population thresholds were used. BA1 and BS1 are not met because the observed frequencies remain below 0.05 and 0.01, respectively; PM2 is not met because all-comers and non-cancer frequencies exceed 0.0001. BS2 remains not assessed because homozygote observations lack documented age, health status, inheritance-model context, and penetrance information.